Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temanogrel in Raynaud's Phenomenon Secondary to Systemic Sclerosis
NCT04915950Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Nov 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of temanogrel in Raynaud phenomenon, sponsored by Pfizer. Started Nov 2021; status: terminated.
02
Drugs
temanogrel
03
Conditions
Raynaud phenomenon
Beyond the preview
Go deeper on NCT04915950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04915950.